Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features ; volume:17 ; number:1 ; day:14 ; month:12 ; year:2021 ; pages:69-84 ; date:1.2022
Targeted oncology ; 17, Heft 1 (14.12.2021), 69-84, 1.2022
- Creator
-
Shirley, Matt
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-021-00857-8
- URN
-
urn:nbn:de:101:1-2022050509431961661223
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shirley, Matt
- SpringerLink (Online service)
Other Objects (12)
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Role of Bruton’s tyrosine kinase in B cells and malignancies
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Targeting CD22 for B-cell hematologic malignancies
Editorial: Targeting bruton tyrosine kinase
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Role of Bruton’s tyrosine kinase in B cells and malignancies
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Targeting CD22 for B-cell hematologic malignancies
Editorial: Targeting bruton tyrosine kinase
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Role of Bruton’s tyrosine kinase in B cells and malignancies
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Targeting CD22 for B-cell hematologic malignancies
Editorial: Targeting bruton tyrosine kinase
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML